Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.58 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15573135 | 0.91 | DDR2 (0.71) | DDR2CARM1PRMT6KMT2AGAA | |
| SCHEMBL16990660 | 0.91 | DDR2 (0.58) | DDR2CARM1PRMT6KMT2APKM | |
| SCHEMBL15574614 | 0.85 | DDR2 (0.68) | DDR2CARM1PRMT6KMT2AGAA | |
| SCHEMBL15573117 | 0.82 | DDR2 (0.56) | DDR2CARM1PRMT6KMT2APYGL | |
| SCHEMBL16990622 | 0.82 | DDR2 (0.84) | DDR2KMT2APOLBMEN1PKM | |
| SCHEMBL15575381 | 0.82 | DDR2 (0.71) | DDR2CARM1PRMT6KMT2APKM | |
| SCHEMBL16990725 | 0.81 | DDR2 (0.56) | DDR2CARM1PRMT6KMT2AMEN1 | |
| SCHEMBL15574694 | 0.81 | DDR2 (0.70) | DDR2KMT2AGAAPYGLPYGM | |
| SCHEMBL16990652 | 0.81 | DDR2 (0.64) | DDR2CARM1PRMT6PYGLPYGM | |
| SCHEMBL16990590 | 0.81 | DDR2 (0.70) | DDR2KMT2APYGLPYGMPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885CARM1 2530/4885PRMT6 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.